Q2-rapport
6 dagar sedan
Orderdjup
Antal
Köp
100
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
3,94VWAP
Lägst
3,45OmsättningAntal
4,6 2 712 014
VWAP
Högst
3,94Lägst
3,45OmsättningAntal
4,6 2 712 014
Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 14 aug. | |
| 2025 Årsstämma | 20 juni | |
| 2025 Q1-rapport | 9 maj | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 21 mars |
Data hämtas från Morningstar, Quartr
Kunder har även besökt
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
4 aug.4 aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
30 jan.30 jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”- 29 jan.29 jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q2-rapport
6 dagar sedan
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 4 aug.4 aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30 jan.30 jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29 jan.29 jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Antal
Köp
100
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
3,94VWAP
Lägst
3,45OmsättningAntal
4,6 2 712 014
VWAP
Högst
3,94Lägst
3,45OmsättningAntal
4,6 2 712 014
Mäklarstatistik
Ingen data hittades
Kunder har även besökt
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 14 aug. | |
| 2025 Årsstämma | 20 juni | |
| 2025 Q1-rapport | 9 maj | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 21 mars |
Data hämtas från Morningstar, Quartr
Q2-rapport
6 dagar sedan
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 14 aug. | |
| 2025 Årsstämma | 20 juni | |
| 2025 Q1-rapport | 9 maj | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 21 mars |
Data hämtas från Morningstar, Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 4 aug.4 aug.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30 jan.30 jan.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29 jan.29 jan.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Antal
Köp
100
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
3,94VWAP
Lägst
3,45OmsättningAntal
4,6 2 712 014
VWAP
Högst
3,94Lägst
3,45OmsättningAntal
4,6 2 712 014
Mäklarstatistik
Ingen data hittades